This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The type and frequency of AEs, ADRs, SAEs, SADRs, UAEs, UADRs, USAEs, USADRs, AESI
Timeframe: Up to 15 years post-infusion
Identify participants for chimeric antigen receptor (CAR) transgene detection and/or CAR surface expression (if applicable).
Timeframe: Up to 15 years post-infusion
Identify presence of replication competent lentivirus (RCL) in blood or tissues
Timeframe: Up to 15 years post-infusion